RGCC International

25/09/2025

Relive the highlights from the International Gathering 2025! From 12–14 September in Zurich, we brought together 130+ participants from 34 countries to share breakthroughs in diagnostics, autologous treatments, and collaborative research.

A heartfelt thank you to our speakers, collaborators, and participants for making this year’s Gathering such a success.

🎥 This recap video captures the energy, innovation, and global spirit that defined three inspiring days of science and collaboration. Watch it here:

17/09/2025

We're proud to announce the successful conclusion of the International Gathering 2025, held from 12–14 September 2025 in Zurich.

This year’s Gathering welcomed over 130 participants from 34 countries, making it Europe’s largest and most dynamic meeting of RGCC scientists, clinicians, and collaborators. Over the course of three inspiring days, we explored cutting-edge advancements in diagnostics and autologous treatments, shared clinical insights, and strengthened global collaboration in the fight against cancer.

We are deeply grateful to everyone who contributed to the success of this event. Together, we continue moving closer to a future where science and innovation redefine possibilities in cancer care.

📸 Explore some highlights here.

15/09/2025

🎗️September is Thyroid Cancer Awareness Month 🎗️

Did you know?
Thyroid cancer is often diagnosed at a younger age than many other cancers. It is also more common in women than in men.

The two most common types, Papillary Carcinoma and Follicular Carcinoma, are usually very treatable, especially when detected early.

📖 Learn more about thyroid cancer and its treatments here: https://www.cancer.org/cancer/types/thyroid-cancer/about/what-is-thyroid-cancer.html

12/09/2025

The RGCC International Gathering 2025 begins today in Zurich, bringing together brilliant minds, groundbreaking ideas and a shared vision for a better future in healthcare. Exciting days ahead 🇨🇭

11/09/2025

RGCC is proud to partner with Indonesia's Universitas Hasanuddin, building a foundation for joint academic efforts.
In May 2025, we signed a Letter of Intent to formalize this partnership.
We invite you to hear from Prof. Dr. Rina Masadah, a key leader at the university, on the importance of this new joint venture.

09/09/2025

🌍 RGCC Signs Letter of Intent with Universitas Hasanuddin and PT Wapindo Jasaartha

In May 2025, RGCC International signed a Letter of Intent (LoI) with Universitas Hasanuddin (Indonesia) and PT Wapindo Jasaartha (Klinik Simas Sehat), marking the beginning of a collaborative academic partnership.

This partnership reflects a shared commitment to fostering international academic collaboration and enabling knowledge exchange across institutions in regards to advanced cancer diagnostic technologies.

Learn more:

RGCC International is proud to announce the signing of a Letter of Intent (LoI) with Universitas Hasanuddin in Indonesia and PT Wapindo Jasaartha (Klinik Simas Sehat), marking the beginning of a collaborative academic partnership.

04/09/2025

Have you explored our study on adjusting second-line treatment for advanced pancreatic using circulating cells (CTCs)?

Developed through a collaboration between scientists and clinical oncologists, this study investigates the potential of to guide second-line chemotherapy decisions in advanced pancreatic , offering a personalized approach.

👉 Click here to read all our published studies: rgcc-international.com/published-articles/

02/09/2025

Our focus is on empowering doctors and patients with personalized insights. At , our advanced blood tests are designed to detect, analyze, and monitor cells at every stage, helping guide treatment with greater precision.

Learn more about our screening tests: rgcc-international.com/tests/

26/08/2025

Colorectal cancer remains one of the most common yet preventable forms of worldwide. With advances in screening technology, lifestyle interventions, and early detection methods, we now have more tools than ever to prevent this disease or catch it at its earliest, most treatable stages.

Read this guide to explore the latest prevention strategies and available screening options:

Choosing an RGCC-certified practitioner can be crucial for your cancer care. Learn how specialized training in advanced testing and personalized medicine can optimize your outcomes.

20/08/2025

Our Founder and Director, Dr. Ioannis Papasotiriou, was featured on "A Healthy Point of View" Podcast with Samael Tejada and Dr. Christopher Davis.

This episode explores how ’s advanced cancer screening tools are transforming early detection and personalized therapy.

📺 Watch the full episode:

In this groundbreaking episode of A Healthy Point of View, host Sam Tejada is joined by the CMO of Liquivida who is an interventional cardiologist, Dr. Chris...

13/08/2025

Have you read our recent study: Evaluation of the effect of benzaldehyde derivatives in human cancer cells?

The study evaluates the effect of a commercial formulation of benzaldehyde and its derivatives on the proliferation of lung and prostate cells.

📈 Read the article and all our published studies here: https://rgcc-international.com/published-articles/

01/08/2025

🫁 Marking 🫁

Lung cancer remains the leading cause of cancer-related deaths worldwide, with over 2.2 million diagnoses and 1.8 million deaths reported in 2020 alone. Often detected too late, lung presents ongoing challenges, but advances in diagnostics, conventional therapies, and personalized approaches are offering new hope.

Our latest patient guide, “Treatment of lung cancer: established methods and new therapy options,” explores current challenges and the evolving landscape of lung cancer care.

🔗 Read it here: rgcc-international.com/patient-information/lung-cancer-therapy/